These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 30782032)
1. BRAF in the cross-hairs. Geyer MB; Abdel-Wahab O; Tallman MS Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032 [TBL] [Abstract][Full Text] [Related]
2. BRAF inhibitor therapy in HCL. Dietrich S; Zenz T Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903 [TBL] [Abstract][Full Text] [Related]
9. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. Falini B; De Carolis L; Tiacci E Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639 [TBL] [Abstract][Full Text] [Related]
10. New Targeted Therapy Combination Holds Promise to Untangle Hairy Cell Leukemia. Soong D; Taylor J NEJM Evid; 2023 Oct; 2(10):EVIDe2300173. PubMed ID: 38320184 [TBL] [Abstract][Full Text] [Related]
11. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. Tiacci E; Park JH; De Carolis L; Chung SS; Broccoli A; Scott S; Zaja F; Devlin S; Pulsoni A; Chung YR; Cimminiello M; Kim E; Rossi D; Stone RM; Motta G; Saven A; Varettoni M; Altman JK; Anastasia A; Grever MR; Ambrosetti A; Rai KR; Fraticelli V; Lacouture ME; Carella AM; Levine RL; Leoni P; Rambaldi A; Falzetti F; Ascani S; Capponi M; Martelli MP; Park CY; Pileri SA; Rosen N; Foà R; Berger MF; Zinzani PL; Abdel-Wahab O; Falini B; Tallman MS N Engl J Med; 2015 Oct; 373(18):1733-47. PubMed ID: 26352686 [TBL] [Abstract][Full Text] [Related]
12. Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University. Ferenczi K; Nagy ZF; Istenes I; Eid H; Bödör C; Timár B; Demeter J Pathol Oncol Res; 2023; 29():1611378. PubMed ID: 38025907 [No Abstract] [Full Text] [Related]
17. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Dietrich S; Pircher A; Endris V; Peyrade F; Wendtner CM; Follows GA; Hüllein J; Jethwa A; Ellert E; Walther T; Liu X; Dyer MJ; Elter T; Brummer T; Zeiser R; Hermann M; Herold M; Weichert W; Dearden C; Haferlach T; Seiffert M; Hallek M; von Kalle C; Ho AD; Gaehler A; Andrulis M; Steurer M; Zenz T Blood; 2016 Jun; 127(23):2847-55. PubMed ID: 26941398 [TBL] [Abstract][Full Text] [Related]
18. New insights in the management of patients with hairy cell leukemia. Cornet E; Damaj G; Troussard X Curr Opin Oncol; 2015 Sep; 27(5):371-6. PubMed ID: 26154707 [TBL] [Abstract][Full Text] [Related]
19. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. Tiacci E; De Carolis L; Simonetti E; Capponi M; Ambrosetti A; Lucia E; Antolino A; Pulsoni A; Ferrari S; Zinzani PL; Ascani S; Perriello VM; Rigacci L; Gaidano G; Della Seta R; Frattarelli N; Falcucci P; Foà R; Visani G; Zaja F; Falini B N Engl J Med; 2021 May; 384(19):1810-1823. PubMed ID: 33979489 [TBL] [Abstract][Full Text] [Related]
20. Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. Itamura H; Ide M; Sato A; Sueoka-Aragane N; Sueoka E; Nishida A; Masunari T; Aoki S; Takizawa J; Suzumiya J; Kimura S Int J Hematol; 2018 Oct; 108(4):416-422. PubMed ID: 30043333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]